DDInter605 DDInter856
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Drotrecogin alfa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Tirofiban
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Alteplase
Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Capsicum
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Drotrecogin alfa may lead to a major life threatening interaction when taken with Tirofiban
Drotrecogin alfa may lead to a major life threatening interaction when taken with Alteplase